Medical AI apps
28 – 34OpenEvidence by 6
| Dimension | Heidi Health | OpenEvidence | Gap |
|---|---|---|---|
| Validation & scaleIndependent published evaluation, peer-reviewed study record, installed clinician base and years in the field. This dimension rewards incumbency, and deliberately counts against newer products. | 4 | 9 | -5 |
| Evidence & citationsWhether claims carry retrievable peer-reviewed citations, how tightly the corpus is controlled, and whether you can get from a sentence in the answer to the paper behind it in one tap. | 6 | 9 | -3 |
| Reasoning transparencyWhether the app shows the steps between your question and its answer — an inspectable chain of thought, a ranked differential with the discriminators named — or returns a conclusion you have to accept on trust. | 4 | 3 | +1 |
| Access & eligibilityPublished price, free tier, credential and country gating, and language coverage — in short, whether the clinician reading this page can actually install and use it today. | 8 | 7 | +1 |
| Scope in one appHow many distinct clinical jobs the single app covers: question answering, differential diagnosis, treatment planning, documentation, lab and imaging interpretation, and programmatic access. | 6 | 6 | — |
Heidi Health
- Best for
- Clinicians whose primary problem is the note rather than the question, working across the US, Canada, Australia and the UK, with documentation support in more than 100 languages.
- Limitation
- Built for documentation first, so evidence retrieval and reasoning are secondary; the free plan's usage caps are restrictive enough that sustained use requires the paid tier.
- Price
- Free plan with usage caps; Pro from about $99/year
OpenEvidence
- Best for
- Verified US clinicians who want a fast, free answer drawn strictly from peer-reviewed literature, with journal content partnerships behind it and an Epic embed already live at a number of health systems.
- Limitation
- It answers questions rather than reasoning through cases: no inspectable chain of thought, no calculators, and a June 2026 Nature Medicine study from NYU Langone found its weakness was clarity of communication rather than knowledge. Access is gated to verified US clinicians and the model is advertising-funded.
- Price
- Free, funded by pharmaceutical advertising
